MedTrace Logo

Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.

NCT00150696 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2007-11-21

No results posted yet for this study

Summary

The purpose of this study is to find out if Risedronate works to prevent osteoporosis after spinal cord injury.

Conditions

  • Acute Spinal Cord Injury.

Interventions

DRUG

Risedronate

Sponsors & Collaborators

  • Ontario Neurotrauma Foundation

    collaborator OTHER

  • St. Joseph's Healthcare Foundation

    collaborator OTHER

  • Queen Elizabeth Hospital NHS Foundation Trust

    collaborator OTHER

  • Toronto Rehabilitation Institute

    lead OTHER

Principal Investigators

  • B. Cathy Craven, MD, FRCPC · Toronto Rehabilitation Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-02-29
Completion
2005-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150696 on ClinicalTrials.gov